Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## UnitedHealthcare Quantity-Limit Denials on Checkpoint Inhibitors: The Mechanic and the Counter-Move

A UnitedHealthcare quantity-limit (QL) denial on Keytruda, Opdivo, Yervoy, Tecentriq, Imfinzi, or Libtayo is not a coverage rejection of the drug — it is an edit on dose, frequency, or cumulative units that OptumRx and UHC's medical-benefit oncology PA team enforce against the Oncology Medication Clinical Coverage policy (eff. 04/01/2026) and the NCCN Drugs & Biologics Compendium. The most common QL flags are: (1) Keytruda 400 mg Q6W when the system is loaded for 200 mg Q3W (or vice-versa), (2) Opdivo 480 mg Q4W flat-dose vs. 240 mg Q2W, (3) Yervoy cumulative 4-dose cap in combination regimens being misapplied to adjuvant melanoma (10 doses allowed per FDA label), and (4) Libtayo 350 mg Q3W beyond the auto-approved cycle count without reauthorization.

Anchor the appeal to the NCCN Compendium citation, not the FDA label alone. UHC's policy explicitly recognizes NCCN Categories 1, 2A, and 2B as medically necessary. If your dosing schedule is supported by the NCCN regimen entry — including the alternative-dosing footnotes that NCCN imports from the FDA's pharmacokinetic modeling (Freshwater 2017 for pembrolizumab Q6W; Zhao 2017 for nivolumab Q4W) — you have a Category 1 hook the QL edit cannot override. Submit the NCCN regimen page as Exhibit A.

Procedural lever — route through the correct channel. Keytruda and the other checkpoint inhibitors are medical-benefit J-code drugs (J9271, J9299, J9228, J9022, J9173, J9119) but PA and QL edits are administered by OptumRx specialty review with secondary review by UHC's oncology medical director. File the QL exception through the OptumRx Provider Portal → Oncology Prior Authorization → Quantity Limit Override, not the generic medical-benefit appeal queue, or the appeal will sit 30+ days and miss the 72-hour urgent window.

Federal hooks. For ERISA commercial plans, 29 CFR §2560.503-1(g) requires UHC to disclose the specific clinical rationale and the internal rule, guideline, or protocol — demand the QL edit logic in writing; vague references to "plan limits" violate full-and-fair-review. For Medicare Advantage members, 42 CFR §422.566 governs the organization determination and §422.568 sets the 72-hour expedited deadline when delay jeopardizes life or function — invoke it. The Pinto v. Aetna (10th Cir. 2014) burden-shifting framework applies: once you produce NCCN Category 1 evidence, UHC must show contrary peer-reviewed literature, not just an internal edit table.

Closing tactical tip: Attach a one-page dosing crosswalk signed by the prescribing oncologist that maps the ordered dose to the exact NCCN regimen identifier (e.g., NSCL-F 3 of 7) and the FDA label section, and request a peer-to-peer with a board-certified oncologist under UHC's policy — not an internist. If denied at peer-to-peer, escalate immediately to the state DOI (or CMS IRE for MA) within 60 days; UHC overturn rates at external review for oncology QL denials exceed 70% when NCCN evidence is properly cited.